

## Supplementary Online Content

Singh N, Ding L, Devera J, Magee GA, Garg PK. Prescribing of statins after lower extremity revascularization procedures in the US. *JAMA Netw Open*. 2021;4(12):e2136014. doi:10.1001/jamanetworkopen.2021.36014

**eTable 1.** Baseline Characteristics of Patients Undergoing Lower Extremity Revascularization

**eTable 2.** Baseline Characteristics of Patients Presenting for Revascularization Based on Intervention Type

**eTable 3.** Multiple Imputation Analysis of Factors Associated With the Prescription of New Statin Therapy Following Lower Extremity Intervention

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Baseline Characteristics of Patients Undergoing Lower-Extremity Revascularization

<b>Variable</b>	<b>Statin post-procedure (n = 139,900)</b>	<b>No statin post-procedure (n = 32,125)</b>	<b>P-Value</b>
<b>Age (years)</b>	67.6 ± 10.6	67.7 ± 12.9	0.28
<b>Sex</b>			< 0.01
Male	89,169 (63.7)	18,631 (58.0)	
Female	50,730 (36.3)	13,492 (42.0)	
<b>BMI (kg/m<sup>2</sup>)</b>	27.9 ± 5.5	26.7 ± 5.6	< 0.01
<b>Race</b>			< 0.01
White	110,348 (78.9)	25,057 (78.0)	
Black	21,629 (15.5)	5,348 (16.7)	
Other	7,822 (5.6)	1,702 (5.3)	
<b>Region</b>			< 0.01
North	45,893 (32.8)	8,850 (27.6)	
East	53,841 (38.5)	13,903 (43.3)	
South	26,736 (19.1)	5,823 (18.1)	
West	13,307 (9.5)	3,539 (11.0)	
<b>Insurance</b>			0.28
Medicare	71,273 (51.0)	16,589 (51.6)	
Medicaid	10,518 (7.5)	2,368 (7.4)	
Commercial	52,766 (37.0)	11,807 (36.8)	
Other	5,273 (3.8)	1,241 (3.9)	
<b>Smoking</b>			< 0.01
Current	50,084 (35.8)	12,602 (39.2)	
Prior	65,176 (46.6)	12,044 (37.5)	
Never	24,509 (17.5)	7,440 (23.2)	
<b>Diabetes</b>			< 0.01
Diet-controlled	6,144 (4.4)	1,498 (4.7)	
Oral Medications	25,265 (18.1)	4,257 (13.3)	
Insulin-Dependent	42,802 (30.6)	6,941 (21.6)	
No	65,636 (46.9)	19,418 (60.5)	
<b>Hypertension</b>	125,685 (89.8)	25,621 (79.8)	< 0.01
<b>Coronary Heart Disease</b>	68,981 (49.3)	8,901 (27.7)	< 0.01
<b>Heart Failure</b>	27,231 (19.5)	4,700 (14.6)	< 0.01
<b>COPD</b>	39,612 (28.3)	8,154 (25.4)	< 0.01
<b>Renal Impairment</b>	3,805 (2.7)	850 (2.7)	0.69
<b>Prior Peripheral Revascularization</b>	74,798 (53.5)	12,293 (44.5)	< 0.01

<b>Antiplatelet Therapy</b>	118,138 (84.4)	21,059 (65.6)	< 0.01
<b>ACE-I or ARB</b>	77,041 (55.1)	12,632 (39.3)	< 0.01
<b>Indication</b>			< 0.01
Asymptomatic	3,958 (2.8)	966 (3.0)	
Claudication	54,755 (39.1)	10,785 (33.6)	
CLTI	70,365 (50.3)	16,881 (52.6)	
Acute Ischemia	10,536 (7.5)	3,398 (10.6)	
<b>Urgency</b>			< 0.01
Elective	116,485 (83.3)	25,797 (80.3)	
Non-Elective	23,281 (16.6)	6,289 (19.6)	

BMI = body mass index, COPD = chronic obstructive pulmonary disease, ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CLTI = chronic limb-threatening ischemia

**eTable 2.** Baseline Characteristics of Patients Presenting for Revascularization Based on Intervention Type

Variable	Surgical Intervention (n = 12,439)		Endovascular Intervention (n = 29,581)	
	Post-Procedure Statin (n=5,045)	No Post- Procedure Statin (n=7,394)	Post-Procedure Statin (n=7,745)	No Post- Procedure Statin (n=21,836)
<b>Age (years)</b>	64.5 ± 11.0	64.7 ± 12.9	66.8 ± 12.0	68.7 ± 12.9
<b>Sex</b>				
Male	3,501 (69.4)	4,892 (66.2)	4,615 (59.6)	11,969 (54.8)
Female	1,544 (30.6)	2,500 (33.8)	3,130 (40.4)	9,867 (45.2)
<b>BMI (kg/m<sup>2</sup>)</b>	26.6 ± 5.3	26.4 ± 5.4	27.2 ± 5.8	26.7 ± 5.6
<b>Race</b>				
White	3,917 (77.6)	5,958 (80.6)	5,786 (74.7)	16,882 (77.3)
Black	861 (17.1)	1,139 (15.4)	1,376 (17.8)	3,703 (17.0)
Other	253 (5.0)	289 (3.9)	578 (7.5)	1,244 (5.7)
<b>Region</b>				
North	1,515 (30.0)	1,754 (23.7)	2,655 (34.3)	6,368 (29.2)
East	1,576 (31.2)	2,885 (39.0)	2,800 (36.2)	9,703 (44.4)
South	1,403 (27.8)	2,073 (28.0)	1,188 (15.3)	3,139 (14.4)
West	522 (10.4)	675 (9.1)	1,102 (14.2)	2,626 (12.0)
<b>Insurance</b>				
Medicare	2,185 (43.3)	3,297 (44.6)	3,834 (49.5)	11,714 (53.7)
Medicaid	580 (11.5)	683 (9.2)	729 (9.4)	1,495 (6.9)
Commercial	1,965 (39.0)	2,995 (40.5)	2,645 (34.2)	7,817 (35.8)
Other	311 (6.2)	298 (5.4)	432 (5.6)	723 (3.3)
<b>Smoking</b>				
Current	2,706 (53.6)	3,543 (47.9)	3,291 (42.5)	8,030 (36.8)
Prior	1,656 (32.8)	2,608 (35.3)	2,681 (34.6)	8,173 (37.4)
Never	680 (13.5)	1,242 (16.8)	1,753 (22.6)	5,597 (25.6)
<b>Diabetes</b>				
Diet-controlled	235 (4.7)	303 (4.1)	414 (5.4)	1,076 (4.9)
Oral Medications	675 (13.4)	787 (10.6)	1,135 (14.7)	3,013 (13.8)
Insulin-Dependent	912 (18.1)	1,113 (15.1)	2,106 (27.2)	4,854 (22.2)
No	3,221 (63.9)	5,190 (70.2)	4,086 (52.8)	12,883 (59.0)
<b>Hypertension</b>	4,029 (79.9)	5,615 (75.9)	6,294 (81.3)	17,401 (79.7)
<b>Coronary Heart Disease</b>	1,511 (30.0)	1,747 (23.6)	2,324 (30.0)	5,836 (26.7)
<b>Heart Failure</b>	570 (11.3)	802 (10.9)	1,271 (16.4)	3,303 (15.1)
<b>COPD</b>	1,324 (26.2)	2,034 (27.5)	1,964 (25.4)	5,290 (24.2)

<b>Renal Impairment</b>	94 (1.9)	155 (2.1)	224 (2.9)	580 (2.7)
<b>Prior Revascularization</b>	2,175 (43.1)	3,587 (48.5)	2,741 (35.4)	9,244 (42.3)
<b>Antiplatelet Therapy</b>	2,841 (56.3)	4,537 (61.4)	4,442 (57.4)	14,197 (65.0)
<b>ACE-I or ARB</b>	1,870 (37.1)	2,610 (35.3)	2,955 (38.2)	8,608 (39.4)
<b>Indication</b>				
Asymptomatic	117 (2.3)	330 (4.5)	137 (1.8)	560 (2.6)
Claudication	1,160 (23.0)	1,963 (26.6)	2,294 (29.6)	7,298 (36.3)
CLTI	2,866 (56.8)	3,854 (52.1)	4,380 (56.6)	11,483 (52.6)
Acute Ischemia	883 (17.5)	1,228 (16.6)	915 (11.8)	1,799 (8.2)
<b>Urgency</b>				
Elective	3,668 (72.7)	5,665 (76.6)	5,552 (71.7)	17,909 (82.0)
Non-Elective	1,368 (27.1)	1,718 (23.2)	2,187 (28.2)	3,904 (17.9)

BMI = body mass index, COPD = chronic obstructive pulmonary disease, ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CLTI = chronic limb-threatening ischemia

**eTable 3.** Multiple Imputation Analysis of Factors Associated With the Prescription of New Statin Therapy Following Lower Extremity Intervention

Variable	Endovascular (n = 29,581)		Surgical (n = 12,439)	
	OR (95% CI)	p-value	OR (95% CI)	p-value
<b>Age (years)*</b>				
≤ 59.0 (≤ 57.0)	Ref	-----	Ref	-----
59.1 - 68.6 (57.1-64.7)	1.12 (1.03 – 1.21)	< 0.01	1.18 (1.06 – 1.32)	< 0.01
68.7 - 78.0 (64.7-73.0)	1.06 (0.97 – 1.16)	0.20	1.25 (1.11 – 1.40)	< 0.01
≥ 78.1 (≥ 73.1)	0.81 (0.73 – 0.89)	< 0.01	1.06 (0.93 – 1.20)	0.37
<b>Sex</b>				
Male	Ref	-----	Ref	-----
Female	0.9 (0.85 – 0.96)	< 0.01	0.87 (0.80 – 0.95)	< 0.01
<b>BMI (kg/m<sup>2</sup>)</b>				
≤25	Ref	-----	Ref	-----
25.1-29.9	1.02 (0.95 – 1.09)	0.53	1.06 (0.97 – 1.16)	0.21
≥30	1.12 (1.04 – 1.21)	< 0.01	1.08 (0.98 – 1.20)	0.13
<b>Race</b>				
White	Ref	-----	Ref	-----
Black	1.05 (0.97 – 1.14)	0.21	1.12 (1.01 – 1.25)	0.04
<b>Region</b>				
East	Ref	-----	Ref	-----
North	1.50 (1.40 – 1.61)	< 0.01	1.57 (1.43 – 1.74)	< 0.01
South	1.26 (1.16 – 1.38)	< 0.01	1.18 (1.07 – 1.30)	< 0.01
West	1.47 (1.34 – 1.60)	< 0.01	1.49 (1.29 – 1.71)	< 0.01
<b>Insurance</b>				
Medicare	Ref	-----	Ref	-----
Medicaid	1.23 (1.10 – 1.37)	< 0.01	1.25 (1.08 – 1.44)	< 0.01
Commercial	1.01 (0.94 – 1.07)	0.88	1.02 (0.93 – 1.11)	0.72
Other	1.55 (1.35 – 1.78)	< 0.01	1.13 (0.95 – 1.35)	0.17
<b>Smoking</b>				
Never	Ref	-----	Ref	-----
Current	1.31 (1.21 – 1.43)	< 0.01	1.44 (1.27 – 1.62)	< 0.01
Prior	1.13 (1.05 – 1.22)	< 0.01	1.22 (1.08 – 1.38)	< 0.01
<b>Diabetes</b>				
No	Ref	-----	Ref	-----
Diet-controlled	1.14 (1.00 – 1.29)	0.05	1.19 (0.99 – 1.44)	0.07
Oral Medications	1.16 (1.07 - 1.27)	< 0.01	1.36 (1.21 – 1.54)	< 0.01
Insulin-Dependent	1.25 (1.16 – 1.25)	< 0.01	1.28 (1.14 – 1.43)	< 0.01

<b>Hypertension</b>	1.16 (1.07 – 1.25)	< 0.01	1.19 (1.08 – 1.31)	< 0.01
<b>Coronary Heart Disease</b>	1.25 (1.17 – 1.34)	< 0.01	1.44 (1.31 – 1.57)	< 0.01
<b>Heart Failure</b>	1.01 (0.93 – 1.10)	0.73	0.91 (0.80 – 1.04)	0.16
<b>COPD</b>	1.04 (0.98 – 1.12)	0.22	0.88 (0.80 – 0.96)	0.01
<b>Renal Impairment</b>	0.93 (0.79 – 1.11)	0.43	0.81 (0.62 – 1.07)	0.14
<b>Prior Revascularization</b>	0.77 (0.73 – 0.82)	< 0.01	0.80 (0.74 – 0.86)	< 0.01
<b>Antiplatelet Therapy</b>	0.78 (0.74 – 0.83)	< 0.01	0.83 (0.77 – 0.90)	< 0.01
<b>ACE-I or ARB</b>	0.95 (0.89 – 1.00)	0.07	1.02 (0.93 – 1.11)	0.68
<b>Indication</b>				
Claudication	Ref	-----	Ref	-----
Asymptomatic	0.85 (0.70 – 1.03)	0.09	0.62 (0.49 – 0.78)	< 0.01
CLTI	1.20 (1.12 – 1.28)	< 0.01	1.23 (1.12 – 1.35)	< 0.01
Acute Ischemia	1.36 (1.22 – 1.52)	< 0.01	1.13 (1.00 – 1.29)	0.06
<b>Urgency</b>				
Elective	Ref	-----	Ref	-----
Non-Elective	1.55 (1.45 – 1.67)	< 0.01	1.16 (1.06 – 1.28)	< 0.01

\*Age reported by quartiles, with surgical intervention quartiles shown in parenthesis

BMI = body mass index, COPD = chronic obstructive pulmonary disease, ACE-I = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CLTI = chronic limb-threatening ischemia